Vicky Qu at BioMap considers the use of artificial intelligence in immuno-oncology and how its use can improve conventional drug discover y processes

Lukasz Jaremko from King Abdullah University of Science and Technology, Saudi Arabia explains how using nuclear magnetic resonance to study the dynamics of epigenetic targets may enable drug development that does not kill but resets cancer cells to a benign state

Amy McKee from Parexel considers the need for diversity in oncology clinical trials in order to fully realise the potential of personalised medicine

Dr Mitchell Smith and Dr Julie Dodds tell Pharmafile about recent R&D in the field of blood cancers including follicular lymphoma

Professor Hendrik van Poppel talks to Pharmafile about new campaigns to improve prostate cancer screening, the current standard-of-care treatments and what obstacles still need to be addressed in treatment

Precision medicine and targetted solutions can be utilised to treat cancer, but how can this develop in the future?

How can the benefits of immunotherapy be maximised for each patient?

Novartis UK tells Pharmafile how COVID-19 impacted patient access to oncology treatments, and how the pharma industry can support the NHS

How can precision medicine and personalised treatments improve healthcare in Europe and worldwide?

The UK has seen many innovations in the healthcare sphere, many have which have been in oncology, but what are the next steps in this ever-evolving field?

Pharmafile speaks to Enara Bio: Enara Bio tell Pharmafile about the unmet patient needs in oncology, and how these can be tackled by novel therapies, as well as considering the future of immunotherapy